FDA’s New Biosimilar Action Plan Represents the Next Step for Improving Drug Competition
By EsqSocial Corporation 20/07/18
On July 18, 2018, after months of alluding to the various aspects of an upcoming “Biosimilar Action Plan” as another prong within FDA’s broader Drug Competition Action Plan (DCAP), FDA finally unveiled its plan for stimulating and improving the...
By: Mintz Levin - Health Law & Policy Matters